FDA Approves Durvalumab Plus Standard of Care Chemo for Extensive-Stage SCLC

The FDA approved durvalumab (Imfinzi) as a first-line treatment for adult patients with extensive-stage small cell lung cancer in combination with standard-of-care chemotherapies, etoposide plus either carboplatin or cisplatin.

Source: CancerNetwork - March 30, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news